About us   Contacts   Links   Information in Russian 
Research programms
Journal
Bulletin of the Multinational Center of Quality of Life Research

Bulletin of the Multinational Center of Quality of Life Research





T. I. Ionova, D. A. Fedorenko, T. P. Nikitina, K. A. Kurbatova

Patient-reported outcomes in patients with chronic myeloid leukemia in chronic phase during second-line treatment with dasatinib

The article is focused to preliminary results of the observational study «Quality of life and symptom profile in imatinib-resistant or -intolerant patients with chronic myeloid leukemia during disease-modifying treatment» (2011–2012). Seventy imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase were involved in the preliminary analysis before switching to second-line therapy with dasatinib.

After 12 months of dasatinib treatment a half of patients had complete or partial cytogenetic response. During dasatinib treatment stabilization of quality of life parameters was registered with a slight tendency of improving for vitality and mental health. Quality of life treatment response in terms of improvement or stabilization was observed in the majority of patients (75%). The severity of a number of common disease and treatment-specific symptoms decreased during dasatinib treatment.

This observational study has shown that dasatinib therapy in real everyday practice is effective both in terms of clinical outcomes and patient-reported outcomes; along with that, it has good tolerability. Patient-reported outcomes contribute to comprehensive assessment of treatment efficacy in patients with chronic myeloid leukemia during disease-modifying treatment.




© Создание сайтов

Последнее обновление (last update): 07-12-2021









Яндекс цитирования